A daily oral pill held three-quarters of the weight off after patients stopped weekly GLP-1 injections, the first phase-3 maintenance trial in obesity to put a real number on the rebound problem. ATTAIN-MAINTAIN ↗, presented Tuesday at the European Congress on Obesity 2026 in Istanbul and published the same day in Nature Medicine, randomized 376 US adults who had already completed 72 weeks of weekly tirzepatide ↗ (Mounjaro, Zepbound) or semaglutide ↗ (Ozempic, Wegovy) to either daily oral orforglipron or a matching placebo for another 52 weeks. The orforglipron arm held more of the prior loss in both cohorts, and the cardiometabolic gains held with it.
The numbers. Adults who had been on tirzepatide kept 74.7 percent of their earlier weight loss after switching to orforglipron, versus 49.2 percent on placebo. Adults who had been on semaglutide kept 79.3 percent on orforglipron versus 37.6 percent on placebo. In plain terms, the placebo arms regained roughly half to two-thirds of what they had lost during the injectable phase, while the orforglipron arms regained closer to a fifth to a quarter. Blood pressure, lipid, and glucose improvements achieved during the injectable phase were preserved alongside the weight. Gastrointestinal side effects (nausea, constipation, diarrhea) were the most common adverse signal, mostly mild to moderate, consistent with the broader GLP-1R ↗ agonist class.
Why this is a story. The single largest unsolved problem with Wegovy ↗ and Mounjaro ↗ has been what happens when a patient stops the drug. The prior data, most clearly the STEP 1 extension and the SURMOUNT-4 withdrawal arm, showed that patients regain roughly two-thirds of the lost weight within a year of coming off the jabs. That dynamic has shaped the policy framing of the obesity-drug era, the reimbursement debates, and the lifelong-treatment talking point. ATTAIN-MAINTAIN is the first phase-3 trial to test whether a different drug, taken differently, can hold the loss without keeping the patient on a weekly injection. The answer it returns is yes, with two qualifications.
The first qualification is the comparator. The placebo arms in ATTAIN-MAINTAIN did regain weight, but not all of it. Adults who had completed 72 weeks of weekly GLP-1 therapy held 38 to 49 percent of their loss for a full year even on placebo, which is meaningfully better than older estimates that put twelve-month rebound at two-thirds. Part of that gap is study population, part is the metabolic adjustment patients undergo during a sustained 72-week injectable course, and part is that everyone in ATTAIN-MAINTAIN stayed in trial-grade behavioral support. The orforglipron benefit is real and large in both cohorts, but the placebo-arm number is also useful evidence about what a structured stop can preserve on its own.
The second qualification is the molecule. Orforglipron is not a peptide. It is a non-peptide small-molecule GLP-1 receptor agonist with no fasting or water-restriction requirements on absorption, manufactured at a fraction of the cost per dose of injectable peptides. Eli Lilly priced Foundayo ↗, the obesity formulation, at roughly $149 per month at the lowest dose in the US, against more than $1,000 per month for Wegovy or Zepbound, and it began UAE pharmacy distribution May 12. The maintenance use case fits orforglipron's commercial profile precisely. Patients who lost weight on a $1,000-a-month injectable have a defensible reason to step down to a $149-a-month pill rather than restart from zero, and the trial now reports they will keep most of what they lost.
What the paper does not answer. The follow-up window is 52 weeks. The longer-term question, whether the held weight stays held at year three or year five, is what experts at Cambridge, Anglia Ruskin, and Weill Cornell flagged in the Guardian ↗ and BBC ↗ coverage. Louis Aronne, the trial's lead investigator at Weill Cornell Medicine, told the Guardian the next question is what happens if maintenance therapy starts earlier, before patients reach severe obesity, but that is not what ATTAIN-MAINTAIN tested. The trial was funded by Lilly, the manufacturer of both Mounjaro and orforglipron, and run in a 376-adult US population at a mean age of 48.6. Generalization to older adults, to non-US populations, and to patients with shorter prior injectable exposure remains to be shown.
The same Nature Medicine issue carried a parallel maintenance paper ↗ from Ellen Blaak's group in Maastricht. In a 90-adult Dutch trial, a daily pasteurized Akkermansia muciniphila Muc T supplement held weight loss after an 8-week low-calorie diet phase: bacteria-supplement participants regained 13.6 percent of the lost weight over the next 24 weeks, versus 32.9 percent on placebo. The mechanism is gut-microbiome-mediated rather than receptor agonism, the population is much smaller, and the prior weight-loss intervention is dietary rather than pharmacological. The two papers land in the same issue at the same conceptual layer: the maintenance arc of obesity care now has live phase-3 options on both pharmacological and non-pharmacological axes.
The platform read. The peptidemodel corpus's GLP-1R ↗ and GIPR ↗ target pages anchor the injectable molecules being switched away from in ATTAIN-MAINTAIN. Orforglipron sits at the boundary of the platform's coverage, a non-peptide small molecule binding the same receptor as the peptide GLP-1 analogs. The trial does not change the molecular questions the cards are built on, but it narrows the clinical use case for the injectable peptides in a way reimbursement and prescribing will absorb. The week-72 injectable phase remains the depth-of-loss workhorse. The pill is now the maintenance instrument, and the rebound problem has its first phase-3 answer.